Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Sargramostim + STEMVAC |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| STEMVAC | CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine | STEMVAC is a cancer vaccine that encodes multiple class II epitopes that result in a Th1 response upon expression, potentially leading to enhanced antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10, NCI Drug Dictionary). | ||
| Sargramostim | Leukine | GM-CSF|Prokine |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05455658 | Phase II | Sargramostim + STEMVAC | STEMVAC in Patients With Early Stage Triple Negative Breast Cancer | Active, not recruiting | USA | 0 |
| NCT05242965 | Phase II | Sargramostim Sargramostim + STEMVAC | A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |